On September 08, 2017, the Food and Drug Administration (FDA) approved Parker Hannifin’s request to expand Indego’s indications for use (IFU). This is great news for patients! This expansion is a significant change from the previous FDA approved IFU, and now allows therapists to treat individuals with spinal cord injury at levels C7 and lower in rehabilitation institutions. Furthermore, it enables... Read More »